跳至主要内容
临床试验/RBR-253kcmg
RBR-253kcmg进行中(未招募)不适用

Epigenetic modulation by n-3 polyunsaturated fatty acids and bioactive compounds (Silybum marianum L.) in non-alcoholic fatty liver disease

Universidade Federal do Rio de Janeiro0 个研究点目标入组 72 人开始时间: 2026年9月1日最近更新:
适应症

试验速览

阶段
不适用
状态
进行中(未招募)
入组人数
72

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
19Y 至 0(—)

入选标准

  • Age between 19 and 80 years; diagnosis of metabolic dysfunction-associated steatotic liver disease by abdominal ultrasound and/or liver biopsy within the 24 months prior to the intervention

排除标准

  • Hepatitis with detectable viral load; fever or sites of infection; cancer (with or without chemotherapy and radiotherapy); inflammatory diseases of the gastrointestinal tract; transplant, trauma, surgery, or hospitalization within the last 30 days; use of steroids, non-steroidal anti-inflammatory drugs, immunomodulatory agents, or antibiotics; use of omega-3 fatty acid supplements in the 3 months prior to the study; pregnancy and lactation; alcohol intake exceeding 20 grams/day for women and 30 grams/day for men

研究者

相似试验